In conclusion, the present study demonstrates the hypoglycemic activity of a new synthetic compound benzenesulfonamide derivative that can protect against HFD and STZ-induced type 2 diabetes mellitus in experimental rats, probably via addressing metabolic syndrome, glycogen depositions, insulin sensitivity, and the blood glucose level abnormalities caused by immunological and metabolic assaults. Here, INS is linked to diabetes mellitus.